Related Experiment Videos
Bone loss in adolescents using Depo-Provera.
1University of Texas Southwestern Medical Center, Department of Obstetrics and Gynecology, USA. jwolff1217@aol.com
Journal of the Society of Pediatric Nurses : JSPN
|April 6, 2001
Summary
Depo-Provera (DMPA) use significantly lowers bone density in adolescents up to age 21. This is a concern for those with disabilities who may already be at high risk for osteoporosis.
Area of Science:
- Women's Health
- Adolescent Medicine
- Endocrinology
Background:
- Declining bone density is a growing concern, particularly in women.
- Certain contraceptive methods may exacerbate this issue in calcium-deficient populations.
- Adolescents, especially those with disabilities, are a vulnerable group for bone health issues.
Purpose of the Study:
- To investigate the impact of Depo-Provera (DMPA) on bone mineral density (BMD) in adolescents.
- To assess the implications of DMPA use in adolescents with disabilities who are at higher risk for osteoporosis.
Main Methods:
- The study focused on adolescents up to age 21.
- Analysis of bone mineral density changes associated with DMPA use.
Main Results:
- Depo-Provera (DMPA) use was found to significantly decrease bone mass density (BMD) in normal adolescents up to age 21.
- The effects of DMPA on BMD in adolescents with disabilities are presumed similar to able-bodied adolescents, though research is limited.
Conclusions:
- Depo-Provera (DMPA) poses a risk to adolescent bone health, significantly reducing BMD.
- Early identification of risk factors and proactive management, including nutrition, exercise, and lifestyle counseling, are crucial for primary care providers.
- Optimizing BMD in adolescents using DMPA requires a comprehensive approach to mitigate osteoporosis risk.